Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852652 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A3SOS1F2RALDH1A1 | |
| SCHEMBL2708451 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL30301996 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL29280610 | 0.82 | CES2 (0.44) | F2RALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL112046 | 0.81 | CES2 (0.61) | SLC6A4SLC6A3ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL861495 | 0.81 | PTPN2 (0.54) | SLC6A3ALDH1A1L3MBTL1RAB9ACYP1A2 | |
| SCHEMBL1656936 | 0.81 | TSHR (0.55) | F2RALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL485869 | 0.80 | F2R (0.44) | F2RNPC1RAB9ASMN1; SMN2CES2 | |
| SCHEMBL1367028 | 0.79 | CA12 (0.67) | SLC6A4SLC6A3ALDH1A1NPC1RAB9A | |
| SCHEMBL31258832 | 0.79 | CA12 (0.67) | SLC6A4SLC6A3ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854631-B | 4-Aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2025-04-15 | — | — | CN | claimed |
| CN-116854631-A | 4-aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2023-10-10 | — | — | CN | claimed |
| US-20230136155-A1 | CONJUGATION-FUSED BIPOLAR REDOX-ACTIVE MOLECULE, PREPARATION METHOD, AND APPLICATION THEREOF | UNIV HANGZHOU NORMAL (CN) | 2023-05-04 | — | — | US | claimed |
| CN-114456195-B | Conjugated fusion bipolar redox active molecule and preparation method and application thereof | 杭州师范大学 | 2023-04-18 | — | — | CN | claimed |
| CN-114456195-A | Conjugated fusion bipolar redox active molecule and preparation method and application thereof | 杭州师范大学 | 2022-05-10 | — | — | CN | claimed |
| US-8119681-B2 | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | claimed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | claimed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12617804-B2 | Conjugation-fused bipolar redox-active molecule, preparation method, and application thereof | HANGZHOU NORMAL UNIVERSITY (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085070-A1 | HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4705292-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085070-A1 | HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER | CBL, CBLB, CBLC | SLC6A4 2685/4885SLC6A3 2789/4885SOS1 30/4885 |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | SLC6A4 1256/4885SLC6A3 648/4885SOS1 2291/4885 |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | SLC6A4 2678/4885SLC6A3 1884/4885SOS1 98/4885 |
| US-12617804-B2 | Conjugation-fused bipolar redox-active molecule, preparation method, and application thereof | CYBB, ROS1, NDUFS7 | SLC6A4 3279/4885SLC6A3 1743/4885SOS1 4271/4885 |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, NR5A1 | SLC6A4 3740/4885SLC6A3 4227/4885SOS1 3778/4885 |
| US-20230136155-A1 | CONJUGATION-FUSED BIPOLAR REDOX-ACTIVE MOLECULE, PREPARATION METHOD, AND APPLICATION THEREOF | SQOR, NQO1, PPOX | SLC6A4 2556/4885SLC6A3 522/4885SOS1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.